Company / Cash & Equivalents
AbCellera Biologics Inc. Cash & Equivalents History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$128.5M
FY2025
5-year range
$128.5M / $476.1M
FY2021-FY2025
Trend
-17.8%
vs FY2024
Sector context
#123 of 207
Health Care
What the data says
At $129M, AbCellera Biologics Inc.'s cash & equivalents ranks #123 of 207 in the Health Care sector. Declined from $133M to $129M over the past 2 years.
Based on SEC 10-K filings.
$129M in FY2025 with a 5-year CAGR of -26.4%.
Declined from $133M to $129M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -30.7%
- 5-Year CAGR
- -26.4%
- 10-Year CAGR
- -
Sector benchmark
#123 of 207 in Health CareTop 59% of 207This company $128.5M Sector average $669.5M
▼
-80.8% below sector average
Key checks
Key Insights
- 5-year CAGR of -26.4%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 17.8% year-over-year.
- Ranks #123 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2020.
Company context
Key Data Points
- Altman Z-Score 0.93 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $128.5M | -17.8% |
| FY2024 | $156.3M | +17.3% |
| FY2023 | $133.3M | -65.5% |
| FY2022 | $386.5M | -18.8% |
| FY2021 | $476.1M | -19.9% |
| FY2020 | $594.1M | - |
| FY2019 | - | - |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026